BioNTech partners with Bill and Melinda Gates Foundation, scoring $55M equity investment; BeiGene brushes off short attack
→ Less than two months after German biotech BioNTech raised a herculean $325 million in an upsized round of financing — the Bill and Melinda Gates Foundation have signed a pact with the company, making an initial equity investment of $55 million to develop vaccine and immunotherapy candidates to prevent HIV and tuberculosis. Total funding under the deal could hit $100 million, via potential grant funding from the foundation, BioNTech said on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.